시장보고서
상품코드
1268027

비만 : 파이프라인 애널리틱스(2023년)

Obesity-Pipeline Analytics -2023

발행일: | 리서치사: Mellalta Meets LLP | 페이지 정보: 영문 240 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

비만은 공중보건의 우려 사항이며, 전 세계에서 유병률이 증가하고 있습니다. 현재는 미국 의사회(2013년) 및 유럽위원회(2021년)에 의해 만성질환으로 분류될 만큼 만연이 진행되고 있습니다. 비만은 삶의 질에 큰 영향을 미치고 의료비의 증가로 연결되며, 비만한 사람은 심혈관질환, 2형 당뇨병, 특정 암, 근골격계 장애 등 수많은 건강 리스크를 발병하는 리스크가 높아진다고 합니다.

비만에 대해 조사했으며, 비만의 개요와 파이프라인 동향, 경쟁 구도, 상별 파이프라인 약제 등을 정리하여 전해드립니다.

목차

개요

비만 표적

  • 서론
  • 역학과 원인
  • 비만의 병태생리학
  • 비만의 발증 기서
  • 비만에서 글루카곤 유사펩티드-1(GLP-1)의 역할
  • 2022년 비만 치료 가이드라인
  • 환자에게 가장 적절한 체중감량약을 선택하기 위한 증거에 기반한 권장사항
  • 비만의 잠재적 결과를 따르는 T2D(2형 당뇨병) 시판약

비만 파이프라인 분석, 상별

  • 비만 - 제III상 및 제II상 파이프라인 분석의 개요
  • 파이프라인 제품, 개발 단계별
  • 비만의 경쟁 구도, 상별, 경로별
  • 임상 파이프라인(제3상-제1상) 제품, 기업별
  • 비만의 단독요법과 병용요법 임상시험
  • 파이프라인 제품, 작용기서별
  • 초기 및 임상 단계의 새로운 메커니즘
  • 비만의 임상 및 규제 타임라인
  • 후기 단계 프로파일 비교의 개요

비만 라이선싱, 인수, 협업

비만 파이프라인의 상황

  • 비만 임상 파이프라인 상황

제III상

  • CagriSema(Novo Nordisk A/S)
  • DOR/3 TC/TDF(Merck & Co)
  • Tirzepatide(Eli Lilly and Company)
  • IBI362(Innovent Biologics(Suzhou) Co. Ltd.)

비만 파이프라인 상황

제II상

  • DCCR(Soleno Therapeutics, Inc)
  • MBL949(Novartis)
  • BI 456906(Zealand Pharma/Boehringer Ingelheim)
  • LY3502970(Eli Lilly and Company)
  • XW-003(Sciwind Biosciences)
  • ARD-101(Aardvark Therapeutics)
  • Danuglipron(Pfizer)
  • PF-07081532(Sosei Heptares)
  • Pemvidutide(Altimmune, Inc.)
  • Retatrutide(Eli Lilly and Company)
  • TG103(Genexine/I-Mab Biopharma/CSPC Pharmaceutical)
  • APHD-012(Aphaia Pharma)
  • Bimagrumab(Versanis Bio, Inc./Novartis)
  • HSG4112(Glaceum)
  • SHR20004(Jiangsu HengRui Medicine Co.)
  • AMG-133(Amgen)
  • PYY 1875(Novo Nordisk A/S)
  • Cagrilintide(Novo Nordisk A/S)
  • EMP-16-02(Empros Pharma)

제I상

  • EMP-16-02(Empros Pharma)
  • AMG-786(Amgen)
  • BMS-963272(Bristol-Myers Squibb)
  • DD01(D&D Pharmatech)
  • ERX1000(ERX Pharmaceuticals)
  • GMA106(Gmax Biopharm)
  • LY3457263(Eli Lilly and Company)
  • NNC0247-0829(Novo Nordisk)
  • Amycretin(Novo Nordisk)
  • NO-13065(Otsuka Pharmaceutical Factory, Inc)
  • S-309309(Shionogi)
  • HM15136(Hanmi Pharmaceutical Company Limited)
  • DR10624(Zhejiang Doer Biologics)
  • LY3841136(Eli Lilly and Company)
  • DACRA QW II(Eli Lilly and Company)
  • AZD6234(AstraZeneca)
  • CT-388(Carmot Therapeutics, Inc)
  • INV-202(Inversago Pharma Inc.)
  • BI 1820237(Boehringer Ingelheim)
  • ZP 8396(Zealand Pharma)
  • MVD1(Eolo pharma)
  • VK2735(Viking Therapeutics)
  • GSBR-1290(Structure Therapeutics)
  • XW014(Sciwind Biosciences)
  • CIN-109(CinFina Pharma)
  • CB4211(CohBar)
  • DWP306001(Daewoong Pharmaceutical)
  • LR19021(LG Life Sciences)
  • ECC5004(Eccogene)
  • SCO267(SCOHIA PHARMA, Inc)
  • SCO094(SCOHIA PHARMA, Inc./Huadong Medicine)
  • BC LisPram(Adocia)
  • GUB002496(Gubra Therapeutics/Boehringer Ingelheim)
  • MT961(Medytox)

비만 전임상 파이프라인 상황

비만 SWOT 분석

부록

KSA 23.05.18

Obesity report provides a comprehensive analysis of the obesity market, with an in-depth analysis of key pipeline products, licensing, acquisition, and collaboration deals. The report covers around 120+ products with 50 companies and their 65 products is clinical stages, providing valuable insights to companies seeking to expand their research in this therapy area. In addition, our report provides in-depth profiles of obesity candidates, including preclinical and clinical studies, details of partnerships and business deal values, targeted technologies, investments, and acquisition trends. We also provide licensing opportunities, acquisition trends, and product analysis by phases, company & MOA. Furthermore, the report covers descriptive information on the competitive pipeline landscape.

Obesity is a growing public health concern, with increasing prevalence worldwide. It has become so prevalent that it is now classified by the American Medical Association (2013) and the European Commission (2021) as a chronic disease. Obesity has a significant impact on quality of life and results in increased healthcare costs, with individuals with obesity at increased risk of developing numerous health risks, including cardiovascular disease, type 2 diabetes, certain cancers, and musculoskeletal disorders.

In this report, Mellalta Meets provides an in-depth analysis of Obesity pipeline covering Phase III & Phase II Pipeline Analysis Overview, Pipeline Products by Stage of Development, Obesity Competitive Landscape Distinguished by Phase & Route, Clinical Pipeline Products by Company, Obesity Monotherapy & Combinations Clinical Trials, Pipeline Products by MOA, Novel Mechanisms in Early and Clinical Stages , Obesity Clinical & Regulatory Timelines, Late-Stage Profiles Comparisons At-a-glance, details of partnerships and business deal values and investments. Currently, there are more than 65 candidates under evaluation in clinical and preclinical studies. The major key players operating in the market are Novo Nordisk, Merck & Co, Eli Lilly and Company, and Innovent Biologics (Suzhou) Co. Ltd and many more which have robust clinical pipelines of OBESITY inhibitor candidates. As per analysis, despite the challenges in the pipeline development of obesity, the obesity market looks set to become the next blockbuster pharma category.

Key Highlights of Obesity Report:

  • The Obesity segment is dominated by the pre-clinical assets (XX) which represent XX% of the total development followed by Phase 1 assets (XX) representing XX%, Phase 2 assets (XX) with XX%, discovery (XX) with 13% and Phase 3 (4) representing 3% of the pipeline development in Obesity.
  • The obesity treatment pipeline is marked by a strong presence of US-based biotech companies, accounting for an impressive XX% of all clinical-stage obesity therapies, followed by China and Denmark with XX%. With Eli Lilly leading the pack in product development, closely trailed by Novo Nordisk and Zealand Pharma, the obesity pipeline showcases a robust and diverse range of innovative solutions to address the global obesity epidemic. These industry giants are set to transform the landscape with ground-breaking treatments, tapping into new mechanisms of action and combination therapies for enhanced efficacy and improved patient adherence.
  • Obesity pipeline landscape includes 85% of Monotherapy trials, 3% combination therapy and 12% of Combination/monotherapy trials.
  • The Obesity segment is dominated by the pre-clinical assets (46), phase 1 assets (37), phase 2 assets (24) and phase 3 (4).

Report Coverage:

  • Indication Prioritisation: Obesity market potential based on Indications.
  • Business Transactions & Strategies: Key collaborations and deal values
  • Obesity Pipeline Development: Product Profiles, Clinical Trials & Results
  • Obesity Acquisition Targets
  • Obesity Competitive Intelligence
  • Recent & Upcoming events

TABLE OF CONTENTS

OVERVIEW

The Obesity Target BACKGROUND

  • Introduction
  • Epidemiology & Causes
  • Pathophysiology of Obesity
  • Obesity pathomechanisms
  • Role of Glucagon-like peptide-1 (GLP-1) in obesity
  • 2022 Obesity Treatment Guidelines
  • Evidence-based recommendations for selecting the most appropriate weight loss medications for their patients
  • Marketed Drugs in T2D (Type 2 diabetes) with potential outcomes in Obesity

Obesity PIPELINE ANALYSIS by Phases

  • Obesity - Phase III & Phase II Pipeline Analysis Overview
  • Pipeline Products by Stage of Development
  • Obesity Competitive Landscape Distinguished by Phase & Route
  • Clinical Pipeline (Phase 3 - Phase 1) Products by Company
  • Obesity Monotherapy & Combinations Clinical Trials
  • Pipeline Products by MOA
  • Novel Mechanisms in Early and Clinical Stages
  • Obesity Clinical & Regulatory Timelines
  • Late-Stage Profiles Comparisons At-a-glance

Obesity Licensing, Acquisition And Collaboration

  • Obesity Licensing, Acquisition, and Deal values
  • Obesity Licensing by Transaction type and total amount size by Phases

Obesity Pipeline Landscape

  • Obesity Clinical Pipeline Landscape

Phase III

  • CagriSema (Novo Nordisk A/S)
    • Product Profile
    • Clinical Trials
    • Collaborations
    • Other Developments
  • DOR/3TC/TDF (Merck & Co)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Tirzepatide (Eli Lilly and Company)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • IBI362 (Innovent Biologics (Suzhou) Co. Ltd.)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments

Obesity Pipeline Landscape

Phase II

  • DCCR (Soleno Therapeutics, Inc.)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • MBL949 (Novartis)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • BI 456906 (Zealand Pharma/Boehringer Ingelheim)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • LY3502970 (Eli Lilly and Company)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • XW-003 (Sciwind Biosciences)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • ARD-101 (Aardvark Therapeutics)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Danuglipron (Pfizer)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • PF-07081532 (Sosei Heptares)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Pemvidutide (Altimmune, Inc.)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Retatrutide (Eli Lilly and Company)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • TG103 (Genexine/I-Mab Biopharma/CSPC Pharmaceutical)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • APHD-012 (Aphaia Pharma)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Bimagrumab (Versanis Bio, Inc./ Novartis)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • HSG4112 (Glaceum)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • SHR20004 (Jiangsu HengRui Medicine Co.)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • AMG-133 (Amgen)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • PYY 1875 (Novo Nordisk A/S)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Cagrilintide (Novo Nordisk A/S)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • EMP-16-02 (Empros Pharma)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments

Phase I

  • EMP-16-02 (Empros Pharma)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • AMG-786 (Amgen)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • BMS-963272 (Bristol-Myers Squibb)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • DD01 (D&D Pharmatech)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • ERX1000 (ERX Pharmaceuticals)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • GMA106 (Gmax Biopharm)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • LY3457263 (Eli Lilly and Company)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • NNC0247-0829 (Novo Nordisk)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Amycretin (Novo Nordisk)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • NO-13065 (Otsuka Pharmaceutical Factory, Inc.)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • S-309309 (Shionogi)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • HM15136 (Hanmi Pharmaceutical Company Limited)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • DR10624 (Zhejiang Doer Biologics)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • LY3841136 (Eli Lilly and Company)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • DACRA QW II (Eli Lilly and Company)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • AZD6234 (AstraZeneca)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • CT-388 (Carmot Therapeutics, Inc.)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • INV-202 (Inversago Pharma Inc.)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • BI 1820237 (Boehringer Ingelheim)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • ZP 8396 (Zealand Pharma)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • MVD1 (Eolo pharma)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • VK2735 (Viking Therapeutics)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • GSBR-1290 (Structure Therapeutics)
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • XW014 (Sciwind Biosciences)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • CIN-109 (CinFina Pharma)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • CB4211 (CohBar)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • DWP306001 (Daewoong Pharmaceutical)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • LR19021 (LG Life Sciences)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • ECC5004 (Eccogene)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • SCO267 (SCOHIA PHARMA, Inc.)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • SCO094 (SCOHIA PHARMA, Inc./Huadong Medicine)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • BC LisPram (Adocia)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • GUB002496 (Gubra Therapeutics/Boehringer Ingelheim)
    • Product Profile & Description
    • Collaborations
    • Other Developments
  • MT961 (Medytox)
    • Product Profile & Description
    • Collaborations
    • Other Developments

Obesity Pre-clinical Pipeline Landscape

Obesity SWOT Analysis

Appendix

  • About us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제